Physician profile
Andre Guidry
NPI 1780734475
$6,297.32
in general payments reported to CMS, 2019-2025
46 companies · $968 in 2025
The $968 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $455 · 2021: $768 · 2022: $844 · 2023: $1,268 · 2024: $1,249 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,485.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,011.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $819.90 | 2019-2025 | |
| Abbvie INC. | $630.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $600.04 | 2019-2025 | Farxiga, Fasenra, Breztri |
| Novo Nordisk INC | $509.59 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $450.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.55 | 2019-2025 | Jardiance |
| Amgen INC. | $169.32 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $147.07 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $144.81 | 2019-2025 | Belsomra, Capvaxive, Dificid |
| Esperion Therapeutics, INC. | $144.23 | 2020-2025 | Nexletol |
| Exact Sciences Corporation | $127.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.19 | 2019-2024 | Xifaxan, Trulance |
| Allergan, INC. | $94.80 | 2019-2020 | |
| Mylan Specialty L.P. | $87.53 | 2021-2024 | Yupelri |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Guidry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.